Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Vida Terzić(Inserm), Kévin Bouiller(Centre Hospitalier Universitaire de Besançon), Aline Dechanet(Assistance Publique – Hôpitaux de Paris), Thérèse Staub(Centre Hospitalier de Luxembourg), Julien Poissy(Centre National de la Recherche Scientifique), Nadia Saïdani, Gil Verschelden, Claire Fougerou‐Leurent(Inserm), Jean‐Philippe Lanoix(Centre Hospitalier Universitaire Amiens-Picardie), Agathe Delbove(Centre hospitalier Bretagne Atlantique), Yoann Zerbib(Centre Hospitalier Universitaire Amiens-Picardie), Vincent Fraipont, Michael Joannidis(Innsbruck Medical University), Hélène Espérou(Hôpital Saint-Louis), France Mentré(Université Claude Bernard Lyon 1), Loïc Epelboin(Ecologie des Forêts de Guyane), David Bougon, Evelina Tacconelli(University of Verona), Félix Djossou, Sandrine Couffin-Cadièrgues, Dominique Costagliola(Inserm), Richard Greil(Paracelsus Medical University), Lucie de Gastines(Inserm), Nathan Peiffer‐Smadja(Université Claude Bernard Lyon 1), Bernd Lamprecht(Johannes Kepler University of Linz), Leïla Belkhir, Marie Gousseff(Centre hospitalier Bretagne Atlantique), Joe Miantezila Basilua(Inserm), Drifa Belhadi(Inserm), Maya Hites(Université Libre de Bruxelles), Florence Ader(Université Claude Bernard Lyon 1), Yazdan Yazdanpanah(Inserm), Nicolas Billard(Assistance Publique – Hôpitaux de Paris), Assia Ferrane(Inserm), Pierre-Alexandre Roger(Centre Hospitalier Universitaire Amiens-Picardie), Guilhem Wattecamps, Alpha Diallo, Christelle Delmas(Inserm), Claire Andréjak, Violaine Tolsma(Centre Hospitalier Annecy Genevois), Antoine Altdorfer, Noémie Mercier(Inserm), Charles Burdet(Université Paris Cité)
Cited by 14
Related Papers
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
|Critical Care|2013|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|Intensive Care Medicine|2014|1k